Quest Diagnostics (Madison, NJ) recently announced the availability of a molecular blood test for identifying renal organ-transplant rejection.
Quest Diagnostics (Madison, NJ) recently announced the availability of a molecular blood test for identifying renal organ-transplant rejection.
The Renal Transplant Monitoring laboratory-developed test is designed to help physicians detect kidney failure weeks before conventional tests or clinical symptoms signify damage. The test may potentially improve patient care for kidney transplant patients while helping to lower sizable health care costs associated with renal transplant failure, Quest Diagnostics said in a statement.
The new test is based on the RNA genetic markers forkhead box P3 (FoxP3), granzyme B (GZMB), and perforin (PRF1) licensed exclusively from Beth Israel Deaconess Medical Center, Boston, and Weill Cornell Medical College, New York.
"Molecular diagnostics to noninvasively detect and predict renal-transplant rejection and monitor the efficacy and safety of pharmaceutical drug therapy and treatment withdrawal have the potential to significantly improve treatment and outcomes for renal transplant patients," said Terry Strom, MD, of Harvard Medical School Beth Israel Deaconess Medical Center. "The first molecular test for this purpose has opened the window to new opportunities for personalized and more effective management of renal graft patients."
Dr. Strom and Manikkam Suthanthiran, MD, of Weill Cornell Medical College, have published research demonstrating that certain biomarkers, including FoxP3, are useful in detecting acute cellular rejection of renal transplants.
Dr. Strom is a paid consultant to Quest Diagnostics, and Dr. Suthanthirna is a non-paid consultant to Quest Diagnostics.
Go back to this issue of Urology Times eNews.
Related Content
Targeted kidney cancer drugs may raise risk of fatal side effects
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.